HeartSciences recesives FDA BDD for Aortic Stenosis ECG algorithm
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2025
0mins
FDA Breakthrough Device Designation: HeartSciences has received FDA Breakthrough Device designation for its AI-driven Aortic Stenosis ECG algorithm, which detects moderate-to-severe aortic stenosis.
Clinical Advantages: The algorithm will be integrated into the MyoVista Insights platform, allowing real-time analysis of existing ECG data and improving early diagnosis in underserved areas without the need for additional hardware.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HSCS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HSCS
Wall Street analysts forecast HSCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HSCS is 10.60 USD with a low forecast of 9.20 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.340
Low
9.20
Averages
10.60
High
12.00
Current: 3.340
Low
9.20
Averages
10.60
High
12.00
About HSCS
HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HeartSciences Partners with Cibolo Health for ECG Management
- Partnership Agreement: HeartSciences has partnered with Cibolo Rural Health Networks, selecting MyoVista Insights™ as the endorsed ECG management platform for 123 independent hospitals, enhancing healthcare quality and efficiency.
- Technology Integration: With MyoVista Insights, Cibolo Health's hospitals will modernize ECG workflows, enabling physicians to interpret ECGs more quickly and efficiently, thereby improving clinical decision-making processes.
- Cloud Platform Advantages: MyoVista Insights offers secure cloud-based ECG data management, supporting various devices and file formats, ensuring regulatory-compliant AI-ECG algorithms can be integrated into routine clinical practice, enhancing accessibility to healthcare services.
- Strategic Implications: This collaboration aligns with Cibolo Health's mission to optimize care delivery while also driving HeartSciences' market expansion within high-value networks, strengthening its competitive position in the healthcare information technology sector.
Continue Reading
HeartSciences Submits MyoVista Device to FDA, Advancing AI ECG Technology
- Product Advancement: HeartSciences submitted its MyoVista® wavECG™ device to the FDA for 510(k) clearance at the end of its fiscal second quarter on October 31, 2025, marking a significant regulatory milestone that is expected to accelerate the product's market entry.
- Software Platform Validation: Since its launch in May 2025, the MyoVista Insights™ platform has received strong validation from early adopters and is currently engaged in commercial discussions with several healthcare institutions, with multiple key customer wins expected to be announced soon, further driving revenue growth.
- Market Opportunity: As a Medical Device Data System, MyoVista Insights carries significantly lower regulatory requirements, which is anticipated to substantially reduce the costs and speed of commercial rollout, enabling the company to quickly tap into a multibillion-dollar market opportunity.
- Financial Position: As of October 31, 2025, HeartSciences reported approximately $2.0 million in cash and cash equivalents and $4.2 million in shareholders' equity, and while no meaningful revenue was generated in FQ2 2026, the company is actively advancing its commercialization strategy.
Continue Reading